CARITI, CATERINA
 Distribuzione geografica
Continente #
NA - Nord America 414
EU - Europa 152
AS - Asia 145
Continente sconosciuto - Info sul continente non disponibili 3
AF - Africa 2
SA - Sud America 2
OC - Oceania 1
Totale 719
Nazione #
US - Stati Uniti d'America 412
SG - Singapore 91
IT - Italia 64
IE - Irlanda 29
CN - Cina 24
SE - Svezia 19
FR - Francia 11
IN - India 9
GB - Regno Unito 8
DE - Germania 7
JP - Giappone 7
FI - Finlandia 5
EU - Europa 3
IR - Iran 3
MY - Malesia 3
VN - Vietnam 3
BE - Belgio 2
CA - Canada 2
CO - Colombia 2
NG - Nigeria 2
UA - Ucraina 2
CH - Svizzera 1
ES - Italia 1
HK - Hong Kong 1
ID - Indonesia 1
KR - Corea 1
MK - Macedonia 1
NL - Olanda 1
NZ - Nuova Zelanda 1
PH - Filippine 1
RU - Federazione Russa 1
TW - Taiwan 1
Totale 719
Città #
Chandler 92
Singapore 82
Dublin 29
Santa Clara 22
Ann Arbor 21
Ashburn 20
Columbus 18
Nyköping 14
Medford 10
Princeton 10
Beijing 7
Boston 7
Pescara 7
Catania 6
Hebei 6
Milan 6
Lappeenranta 5
Jacksonville 4
Naples 4
Pune 4
Torino 4
Turin 4
Washington 4
Guangzhou 3
Norwalk 3
Urbino 3
Wilmington 3
Abuja 2
Bogotá 2
Bologna 2
Brussels 2
Dreieich 2
Esslingen am Neckar 2
Florence 2
Guiyang 2
Hangzhou 2
Messina 2
Modena 2
New York 2
Nottingham 2
Putrajaya 2
Rome 2
San Mauro Pascoli 2
Schwerin 2
Arcene 1
Auckland 1
Barcelona 1
Bourne 1
Cambridge 1
Cattolica 1
Central District 1
Chengdu 1
Dong Ket 1
Fagnano Olona 1
Falls Church 1
Greenville 1
Houston 1
Jakarta 1
Kajang 1
Kansas City 1
Katihar 1
Kawasaki 1
Lausanne 1
London 1
Mountain View 1
Mumbai 1
Munich 1
Nijmegen 1
Québec 1
Redmond 1
Redwood City 1
Regina 1
Riverton 1
San Mateo 1
Sandston 1
Seattle 1
Seoul 1
Shenyang 1
Wickford 1
Totale 467
Nome #
Anogenital warts treatment options: a pratical approach 72
Dual-targeted therapy with apremilast and vedolizumab in pyoderma gangrenosum associated with Crohn’s disease 68
Biologic treatment for psoriasis in cancer patients: should they still be considered forbidden? 58
Comparison of Secukinumab and Ixekizumab in psoriasis: a real-life cohort study on the efficacy and drug survival of 445 patients 57
Efficacy, safety, and drug survival of IL-23, IL-17, and TNF-alpha inhibitors for psoriasis treatment: a retrospective study 55
Melanoma management during the covid-19 pandemic emergency: A literature review and single-center experience 54
Infections in Sézary syndrome: A retrospective cohort study of 113 patients 52
Evolution of different clinical patterns of cutaneous lesions in a suspected COVID-19 patient 45
Sezary syndrome: A single center retrospective study with proposal for a clinical score system 43
Real-life comparison between secukinumab and ixekizumab in the treatment of pustular and erythrodermic psoriasis 36
Effectiveness of Brodalumab on Scalp, Palmoplantar, and Genital Psoriasis: A Descriptive Pilot Study 27
Efficacy of anti-IL-23 and anti-IL-17 after adalimumab failure in psoriatic patients 27
"Superresponders" at biologic treatment for psoriasis: A comparative study among IL17 and IL23 inhibitors 26
Brodalumab efficacy in bio-naïve psoriasis patients: real-life experience of 202 subjects up to 48 weeks 25
Drug survival and efficacy of anti-interleukin 23 biologics in psoriasis: a comparative study on different agents 23
Tildrakizumab in real-life shows good efficacy in moderate-to-severe psoriasis regardless of previous use of biologic drugs and joint involvement 21
Risankizumab shows faster response in bio naïve than in bio-experienced psoriatic patients 17
Mask-related acne flares during the COVID era 17
Comparison between brodalumab, secukinumab and ixekizumab effectiveness and drug survival: A real-life experience on 638 patients with psoriasis 11
Drug survival und klinische Wirksamkeit von Secukinumab, Ixekizumab, Brodalumab, Guselkumab, Risankizumab und Tildrakizumab in der Behandlung der Psoriasis: Drug survival and clinical effectiveness of secukinumab, ixekizumab, brodalumab, guselkumab, risankizumab, tildrakizumab for psoriasis treatment 9
Drug survival and clinical effectiveness of secukinumab, ixekizumab, brodalumab, guselkumab, risankizumab, tildrakizumab for psoriasis treatment 6
Drug Survival, Safety, and Effectiveness of Secukinumab for up to 5 Years in Patients with Psoriasis and Psoriatic Arthritis: A Long-Term Real-Life Experience 3
Clinical characteristics and response to biological therapies for inverse psoriasis: a real‐life comparison between the therapeutic effects of anti‐IL‐23 and anti‐IL‐17 agents 2
Totale 754
Categoria #
all - tutte 4.415
article - articoli 0
book - libri 0
conference - conferenze 210
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 4.625


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202017 0 0 0 0 0 0 0 1 1 2 4 9
2020/202114 4 2 2 1 1 0 0 0 0 0 1 3
2021/2022134 6 0 3 3 16 10 13 16 5 4 25 33
2022/2023233 17 28 4 21 19 43 13 20 29 4 17 18
2023/2024162 15 29 13 13 8 20 7 4 2 14 17 20
2024/2025188 3 61 18 44 62 0 0 0 0 0 0 0
Totale 754